Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Eli Lilly stock soared Thursday after the pharmaceutical giant said its new weight-loss pill had cleared a late-stage ...

Clinical results of a GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs.

US-based pharmaceutical company Eli Lilly on Thursday announced that its experimental oral GLP-1 pill, named orforglipron, ...

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in ...

Eli Lilly's oral GLP-1 drug orforglipron met key Phase 3 goals in type 2 diabetes, lowering A1C and weight with a favorable ...

Orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water ...

Lilly said its investigational once-daily pill achieved positive topline results in a late-stage study evaluating the safety and efficacy of orforglipron compared with a placebo in adults with type 2 ...

Other weight loss drugs must be injected, meaning the new pill from pharmaceutical giant Eli Lilly could become patients’ top ...

Shares in Eli Lilly & Co were set to soar on Wednesday on the back of positive results of a late-stage trial of its ...

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...